Sherif Farag

Summary

Affiliation: Indiana University
Country: USA

Publications

  1. pmc In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies
    Sherif S Farag
    Division of Hematology Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Stem Cells Dev 22:1007-15. 2013
  2. pmc Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission
    Sherif S Farag
    Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Biol Blood Marrow Transplant 17:1796-803. 2011
  3. pmc The potential role of Aurora kinase inhibitors in haematological malignancies
    Sherif S Farag
    Division of Hematology and Oncology, Department of Medicine, Indiana University School of Medicine, 840 Westr Walnut St, Indianapolis, IN 46202, USA
    Br J Haematol 155:561-79. 2011
  4. pmc Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma
    Sherif S Farag
    Departments of Internal Medicine and Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, United States
    Leuk Res 33:1475-80. 2009
  5. doi request reprint Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia
    S S Farag
    Division of Hematology and Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Leukemia 25:599-605. 2011
  6. ncbi request reprint Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation
    Navin Wadehra
    Division of Hematology and Oncology, The Ohio State University Hospitals, Columbus, Ohio, USA
    Biol Blood Marrow Transplant 12:1343-9. 2006
  7. doi request reprint Antimyeloma effects of a sesquiterpene lactone parthenolide
    Attaya Suvannasankha
    Hematology and Oncology Division, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Clin Cancer Res 14:1814-22. 2008
  8. ncbi request reprint OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms
    Shuhong Zhang
    Division of Hematology and Oncology, Department of Internal Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Clin Cancer Res 13:4750-8. 2007
  9. pmc Background and future considerations for human cord blood hematopoietic cell transplantation, including economic concerns
    Hal E Broxmeyer
    1 Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana
    Stem Cells Dev 22:103-10. 2013
  10. pmc Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis
    Hal E Broxmeyer
    Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana, USA
    Nat Med 18:1786-96. 2012

Research Grants

Collaborators

Detail Information

Publications13

  1. pmc In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies
    Sherif S Farag
    Division of Hematology Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Stem Cells Dev 22:1007-15. 2013
    ..Systemic DPP-4 inhibition was well tolerated and may enhance engraftment. Optimizing sitagliptin dosing to achieve more sustained DPP-4 inhibition may further improve outcome...
  2. pmc Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission
    Sherif S Farag
    Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Biol Blood Marrow Transplant 17:1796-803. 2011
    ..Strategies that reduce nonrelapse mortality may yield significant improvements in overall survival...
  3. pmc The potential role of Aurora kinase inhibitors in haematological malignancies
    Sherif S Farag
    Division of Hematology and Oncology, Department of Medicine, Indiana University School of Medicine, 840 Westr Walnut St, Indianapolis, IN 46202, USA
    Br J Haematol 155:561-79. 2011
    ....
  4. pmc Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma
    Sherif S Farag
    Departments of Internal Medicine and Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, United States
    Leuk Res 33:1475-80. 2009
    ..At the dose and schedule used, temsirolimus had low single agent activity. Investigation of alternate dosing schedules and use in combinations is indicated...
  5. doi request reprint Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia
    S S Farag
    Division of Hematology and Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Leukemia 25:599-605. 2011
    ..8 mg per kg total dose) for further study as a myeloablative regimen for allogeneic SCT for high-risk acute leukemia...
  6. ncbi request reprint Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation
    Navin Wadehra
    Division of Hematology and Oncology, The Ohio State University Hospitals, Columbus, Ohio, USA
    Biol Blood Marrow Transplant 12:1343-9. 2006
    ..This novel Bu regimen is comparable to other radiation-free preparative regimens in its effectiveness in the control of HD and with a low-risk of early treatment-related mortality...
  7. doi request reprint Antimyeloma effects of a sesquiterpene lactone parthenolide
    Attaya Suvannasankha
    Hematology and Oncology Division, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Clin Cancer Res 14:1814-22. 2008
    ..The sesquiterpene lactone parthenolide targets NF-kappaB. However, its therapeutic potential in MM is not known...
  8. ncbi request reprint OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms
    Shuhong Zhang
    Division of Hematology and Oncology, Department of Internal Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Clin Cancer Res 13:4750-8. 2007
    ..We investigated the in vitro activity of OSU-03012 in multiple myeloma (MM) cells...
  9. pmc Background and future considerations for human cord blood hematopoietic cell transplantation, including economic concerns
    Hal E Broxmeyer
    1 Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana
    Stem Cells Dev 22:103-10. 2013
    ....
  10. pmc Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis
    Hal E Broxmeyer
    Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana, USA
    Nat Med 18:1786-96. 2012
    ..DPP4 inhibition enhanced engraftment in mice without compromising HSC function, suggesting the potential clinical utility of this approach...
  11. doi request reprint From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma
    Shuhong Zhang
    Indiana University School of Medicine, Division of Hematology and Oncology, Department of Medicine, Indianapolis, IN 46202, USA
    Expert Opin Investig Drugs 20:1015-28. 2011
    ..ENMD-2076 is an orally bioavailable, multi-target kinase inhibitor with multiple mechanisms of action, including anti-proliferative and pro-apoptotic activity, and anti-angiogenic effects...
  12. doi request reprint Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma
    Xiaojing Wang
    Division of Hematology and Oncology, Department of Internal Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Br J Haematol 150:313-25. 2010
    ..These results provide preclinical rationale for clinical investigation of ENMD-2076 in MM...

Research Grants2

  1. QMS Technology to Deplete T Cell Alloreactivity
    Sherif Farag; Fiscal Year: 2005
    ..abstract_text> ..